Scholarlink

<p>Hyperglycemia is substantially involved in the occurrence of complications in people with type&#xa0;2 diabetes mellitus. While lifestyle interventions remain the cornerstones of diabetes treatment, most people with type&#xa0;2 diabetes will eventually require pharmacotherapy for improved glycemic management. The definition of individual treatment targets regarding optimal therapeutic efficacy and safety as well as organ-protective effects are the most important factors. These national guidelines summarize the most current evidence-based recommendations for the clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2026)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Martin Clodi,
  • Heidemarie Abrahamian,
  • Felix Aberer,
  • Alexander Bräuer,
  • Kadriye Aydinkoc-Tuzcu,
  • Helmut Brath,
  • Johanna Brix,
  • Heinz Drexel,
  • Peter Fasching,
  • Astrid Feder,
  • Lisa Frühwald,
  • Maria Fritsch,
  • Bernhard Föger,
  • Claudia Francesconi,
  • Elke Fröhlich-Reiterer,
  • Jürgen Harreiter,
  • Sabine Hofer,
  • Florian Höllerl,
  • Friedrich Hoppichler,
  • Joakim Huber,
  • Simone Huber,
  • Susanne Kaser,
  • Alexandra Kautzky-Willer,
  • Antonia Kietaibl,
  • Gerd Köhler,
  • Monika Lechleitner,
  • Michael Leutner,
  • Bernhard Ludvik,
  • Julia K. Mader,
  • Verena Parzer,
  • Bernhard Paulweber,
  • Thomas Pieber,
  • Rudolf Prager,
  • Elisabeth Pucher,
  • Birgit Rami-Merhar,
  • Gersina Rega-Kaun,
  • Michael Resl,
  • Claudia Ress,
  • Michaela Riedl,
  • Michael Roden,
  • Christoph H. Saely,
  • Christian Schelkshorn,
  • Guntram Schernthaner,
  • Harald Sourij,
  • Lars Stechemesser,
  • Thomas Steinmaurer,
  • Harald Stingl,
  • Thomas Stulnig,
  • Martin Tauschmann,
  • Hermann Toplak,
  • Gerlies Treiber,
  • Alexander Vonbank,
  • Thomas C. Wascher,
  • Raimund Weitgasser,
  • Yvonne Winhofer,
  • Sandra Zlamal-Fortunat

摘要

Hyperglycemia is substantially involved in the occurrence of complications in people with type 2 diabetes mellitus. While lifestyle interventions remain the cornerstones of diabetes treatment, most people with type 2 diabetes will eventually require pharmacotherapy for improved glycemic management. The definition of individual treatment targets regarding optimal therapeutic efficacy and safety as well as organ-protective effects are the most important factors. These national guidelines summarize the most current evidence-based recommendations for the clinical practice.